INTAL

This brand name is authorized in Australia, Japan, Turkey, UK.

Active ingredients

The drug INTAL contains one active pharmaceutical ingredient (API):

1	Cromoglicic acid UNII Q2WXR1I0PK - CROMOLYN SODIUM
	Sodium cromoglicate (Cromoglicic acid) inhibits the activation of many of the cell types involved in the development and progression of asthma. Thus, sodium cromoglicate inhibits the release of inflammatory mediators including cytokines from mast cells and reduces the chemotactic activity of eosinophils and neutrophils.
	Read more about Cromoglicic acid

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
INTAL CFC-FREE Pressurised inhalation, suspension	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R03BC01	Cromoglicic acid	R Respiratory system → R03 Drugs for obstructive airway diseases → R03B Other drugs for obstructive airway diseases, inhalants → R03BC Antiallergic agents, excl. corticosteroids
Discover more medicines within R03BC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8334P, 8767K
GB	Medicines & Healthcare Products Regulatory Agency	137771
JP	医薬品医療機器総合機構	2259701G1063
TR	İlaç ve Tıbbi Cihaz Kurumu	8699582750094, 8699809522619, 8699809522633